GeneTherapyLive’s Weekly Rewind – November 26, 2021

Review top news and interview highlights from the week ending November 26, 2021.

CD19+ B-Cell Malignancy Cell Therapy Receives RMAT Designation

In 26 patients with LBCL followed for at least 28 days, the objective response rate (ORR) was 58% with complete responses (CRs) in 38% of patients.

FasTCAR Cell Therapy Granted Orphan Drug Designation for Multiple Myeloma

The designation follows durable responses seen in a phase 1 study of the agent.